Найти книгу: "Pharmaceutical Biotechnology"

With its focus on industrial pharmaceutical research, written by international experts from the industry, this book fills in a gap in the existing literature. It reflects the combination of such pharmaceutical interests as drug delivery, drug targeting, quality and safety management, drug approval and regulation, patenting issues and biotechnology fundamentals. Thus it provides practitioners in pharmaceutical biotechnology with all the relevant information from the shelf. The first part offers a comprehensive survey and review of the rapidly increasing array of biopharmaceuticals derived from the molecular biological approaches now widely available. This is followed by an extra section devoted to the very critical patenting and drug regulation issues. The whole is rounded off by detailed monographs of biotechnologically developed drugs that are already on the market. With a foreword of by Robert Langer, Kenneth J Germeshausen Professor of Chemical and Biomedical Engineering at the Massachusetts Institute of Technology. In 2002, he received the Charles Stark Draper Prize, the highest recognition for an engineer. Professor Langer is member of all three national academies – the Institute of Medicine, the National Academy of Engineering, and the National Academy of Sciences: «The book attempts to provide a balanced view of the biotechnological industry and the number of experts from industry sharing their knowledge and experience with the audience gives the book an outstanding value. All contributors provide with each chapter an up-to-date review on key topics in pharmaceutical biotechnology. This work is not only a valuable tool for the industrial expert but also for all pharmacists and scientists from related areas who wish to work with biotech drugs.»

An in-depth look at big pharma's flagship company The Merck Druggernaut takes readers inside Merck, the world's second most profitable drug company and maker of the world's bestselling drug, Prilosec. Consistently named one of Fortune magazine's Most Admired Companies, Merck struggles to maintain its reputation for being the most ethical of the big drug makers, refusing to slash research and development budgets in the face of declining profits, falling stock market prices, and questionable accounting. Author Fran Hawthorne, one of the leading journalists covering healthcare, has written an excellent examination of a business paragon with much-needed insight on the cutthroat world of pharmaceuticals. It's a story that will interest the business world as well as consumer and healthcare advocates by detailing the vital issues in medicine and healthcare today. More than just a compelling story of success in a difficult industry, more than simply the biography of one of big business's most recognizable names, The Merck Druggernaut takes a thoughtful look at some of the major issues of our time and the way those issues intertwine with the world of business. Fran Hawthorne (New York, NY) is the Assistant Managing Editor at Crain's New York Business. She has been covering business for more than twenty years for such publications as Fortune, BusinessWeek, and Institutional Investor, with a prevailing interest in healthcare and pharmaceuticals. At Crain's, she spearheads the publication of two to three special healthcare issues per year.

The Handbook of Macroalgae: Biotechnology and Applied Phycology describes the biological, biotechnological and the industrial applications of seaweeds. Vast research into the cultivation of seaweeds is currently being undertaken but there is a lack of methodological strategies in place to develop novel drugs from these sources. This book aims to rectify this situation, providing an important review of recent advances and potential new applications for macroalgae. Focusing on the chemical and structural nature of seaweeds the book brings the potentially valuable bioactive nature to the fore. Novel compounds isolated from seaweeds are reviewed to provide an invaluable reference for anyone working in the field.

The book addresses the basics, applications, and manufacturing of plasmid biopharmaceuticals. The survey of the most relevant characteristics of plasmids provides the basics for designing plasmid products (applications) and processes (manufacturing). Key features that the authors include in the book are: i) consistency and clear line of direction, ii) an extensive use of cross-referencing between the individual chapters, iii) a rational integration of chapters, iv) appellative figures, tables and schemes, and v) an updated, but selected choice of references, with a focus on key papers.

Biofilm Eradication and Preventions presents the basics of biofilm formation on medical devices, diseases related to this formation, and approaches pharmaceutical researchers need to take to limit this problem. Split into three parts, the first deals with the development and characterization of biofilm on the surfaces of implanted or inserted medical devices. Questions as to why biofilms form over medical device surfaces and what triggers biofilm formation are addressed. In the second section, the author discusses biofilm-mediated chronic infections occurred in various organs (eyes, mouth, wounds) and pharmaceutical and drug delivery knowledge gained from research in these area. The third part explores pharmaceutical approaches like lipid-and polymer-based drug delivery carriers for eradicating biofilm on device-related infections. In addition, this section also explores the topic of novel small molecule (like iron and its complexes/metal chelators) and a quorum-sensing inhibitors to control medical biofilm formation.

The first book to provide a simple and practical means of valuing biotech companies The book begins with a short history of the biotechnology industry; this is important as although it is about 30 years old, the first company went public only in 1996, so it is possible to plot the course of investment waves and dips It examines the European industry and its evolvement, and draws parallels between the similarities and differences between that and the US Looks at the various companies which make up the biotech industry (therapeutic; life sciences; and the medical technology company) and gives tools for the investor to properly evaluate them Praise for Biotechnology Valuation «Keegan states that the valuation of Biotech companies is as much an art as a science. This brief but comprehensive review of the skills and knowledge required, not of just the financial market and sentiment, but also of the technical attributes of a company and the drug development and regulatory hurdles that must be overcome, highlights the importance of the breadth of understanding required. Biotech investing is not for the timid, but it can bring substantial returns. Keegan's book, punctuated with his personal experience and opinions, is a good place to start.» —Chris Blackwell, Chief Executive, Vectura Group plc «A user-friendly, yet thorough discussion of a notoriously difficult topic. Dr Keegan's book is a fine resource for both business types and academicians.» —Steve Winokur, Managing Director, CanaccordAdams «A highly readable and comprehensive explanation of the technical and commercial parameters that influence biotechnology companies at all stages of development, providing clear context for selection from the toolkit of valuation methodologies the author recommends to assess company and product performance, or ascribe value.» —Dr L.M. Allan, Director, Bioscience Enterprise Programme, University of Cambridge «A fabulous approach to a difficult topic.» —Deirdre Y. Gillespie, MD, President & CEO, La Jolla Pharmaceutical Company